GleamWall
中文EN

MRNA Moderna, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1682852 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.1%
TTM net income YoY10.5%
TTM EPS YoY12.7%
Revenue 3-yr CAGR-34.8%
Net income 3-yr CAGR—

Margins

Gross margin28.0%
Operating margin-116.0%
Net margin-110.5%
FCF margin-78.0%
EBITDA margin-106.6%

Returns

ROE-34.5%
ROA-21.8%
ROIC (approx.)-33.4%
Asset turnover0.20x

Leverage & solvency

Liabilities / assets49.2%
Debt / equity0.00x
Current ratio3.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue7.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.31B$145.00M$389.00M$678.00M$1.02B$142.00M$108.00M$966.00M
Cost of revenue$318.00M$93.00M$955.00M$452.00M$207.00M$119.00M$90.00M$739.00M
Gross profit$995.00M$52.00M-$566.00M$226.00M$809.00M$23.00M$18.00M$227.00M
R&D expense$583.00M$651.00M$649.00M$775.00M$801.00M$700.00M$856.00M$1.12B
SG&A expense$282.00M$216.00M$173.00M$308.00M$268.00M$230.00M$212.00M$351.00M
Operating income$130.00M-$815.00M-$1.39B-$857.00M-$260.00M-$907.00M-$1.05B-$1.25B
Pretax income$171.00M-$767.00M-$1.33B-$799.00M-$187.00M-$818.00M-$964.00M-$1.18B
Income tax$9.00M$15.00M$9.00M$27.00M$13.00M$7.00M$7.00M-$64.00M
Net income$162.00M-$782.00M-$1.34B-$826.00M-$200.00M-$825.00M-$971.00M-$1.12B
EBITDA$191.00M-$759.00M-$1.33B-$791.00M-$209.00M-$851.00M-$1.01B-$1.19B
EPS (basic)0.40-1.97-3.40—-0.51-2.13-2.52—
EPS (diluted)0.38-1.97-3.40—-0.51-2.13-2.52—
Weighted avg. shares (diluted)430.00M398.00M395.00M—390.00M388.00M386.00M—
Balance sheet
Cash & equivalents$1.20B$1.72B$1.91B$2.60B$1.13B$1.28B$1.62B$1.93B
Short-term investments$3.98B$3.42B$3.30B$3.20B$3.37B$3.85B$4.35B$5.10B
Receivables$1.37B$17.00M$71.00M$184.00M$1.05B$36.00M$78.00M$358.00M
Inventory$313.00M$280.00M$146.00M$153.00M$332.00M$240.00M$128.00M$117.00M
Current assets$7.34B$5.82B$5.77B$6.54B$6.60B$6.17B$6.77B$8.10B
PP&E, net$2.04B$2.06B$2.09B$2.13B$2.13B$2.17B$2.21B$2.20B
Goodwill$52.00M$52.00M$52.00M$52.00M$52.00M$52.00M$52.00M$52.00M
Intangibles$102.00M$109.00M$116.00M$45.00M$47.00M$48.00M$49.00M$40.00M
Total assets$13.47B$10.96B$11.49B$12.34B$12.13B$12.01B$12.70B$14.14B
Current liabilities$2.03B$2.53B$2.40B$1.99B$1.68B$1.57B$1.60B$2.21B
Long-term debt—$591.00M$590.00M$590.00M———$0
Total debt—$591.00M$590.00M$590.00M———$0
Total liabilities$6.63B$4.20B$4.08B$3.69B$2.81B$2.61B$2.64B$3.24B
Shareholders' equity$6.84B$6.76B$7.41B$8.65B$9.33B$9.40B$10.07B$10.90B
Net debt—-$1.13B-$1.32B-$2.00B———-$1.93B
Shares outstanding404.00M399.00M397.00M394.00M391.00M389.00M387.00M386.00M
Cash flow statement
Operating cash flow-$1.56B-$526.00M-$630.00M$930.00M-$847.00M-$919.00M-$1.04B$825.00M
Capital expenditure$47.00M$37.00M$62.00M$39.00M$33.00M$3.00M$117.00M$522.00M
Free cash flow-$1.61B-$563.00M-$692.00M$891.00M-$880.00M-$922.00M-$1.15B$303.00M
Investing cash flow-$1.72B$329.00M-$76.00M-$48.00M$700.00M$564.00M$730.00M-$539.00M
Financing cash flow$2.75B$14.00M$17.00M$581.00M-$1.00M$9.00M$4.00M-$3.00M
Depreciation & amortization$61.00M$56.00M$56.00M$66.00M$51.00M$56.00M$38.00M$59.00M
Stock-based compensation$127.00M$120.00M$104.00M$113.00M$125.00M$130.00M$115.00M$104.00M
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.